Back to search

Article

Polygenic Liability for Antipsychotic Dosage and Polypharmacy - A Real-World Registry and Biobank Study

2023-09-25

Abstract excerpt

<title>Abstract</title> <p>Genomic prediction of antipsychotic dose and polypharmacy has been difficult, mainly due to limited access to large cohorts with genetic and drug prescription data. In this proof of principle study, we investigated if genetic liability for schizophrenia is associated with high dose requirements of antipsychotics and antipsychotic polypharmacy, using real-world registry and biobank data...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
14cd210a-d8ca-56bd-abf9-7f1d2082a1f6
DOI
10.21203/rs.3.rs-3308026/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Polygenic Liability for Antipsychotic Dosage and Polypharmacy - A Real-World Registry and Biobank StudyDOI 10.21203/rs.3.rs-3308026/v1
Select a neighboring publication to make it the new centre.